Lupin
Other · 2 quarters tracked · source-linked performance and management context.
Latest revenue
₹7,475 Cr
verified financial record
Quarters tracked
2
source records in the directory
Delivery assessment
0
Across 2 tracked commitments: 0 delivered, 2 missed.
Call date
2026-05-15
latest available source date
Signal trajectory
2 actual quartersCurrent read
0/100
Across 2 tracked commitments: 0 delivered, 2 missed.
Latest source read
What changed this quarter?
Lupin delivered a stellar Q4 FY26 with revenue of ₹7,475 crore (+32% YoY) and EBITDA of ₹2,171 crore (+68% YoY), marking the 15th consecutive quarter of growth. The US business was a standout, reaching $1.31 billion for the full year (+40% YoY), driven by complex generics like Tolvaptan and Mirabegron. India prescription business grew 14.5% YoY, outperforming IPM. Management guided for high single-digit revenue growth and ~25% EBITDA margin in FY27, factoring in competition on key products and higher R&D spend. Key risks include potential generic competition for Mirabegron and Tolvaptan, and inflationary pressures from global trade disruptions.
Colored figures compare against the previous available record. Hover or focus one for the comparison.
Signal
Positive
Revenue
₹7,475 Cr
Source date
2026-05-15
Across the record
Quarter history.
History modules